vs
ADMA BIOLOGICS, INC.（ADMA）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
Ribbon Communications Inc.的季度营收约是ADMA BIOLOGICS, INC.的1.2倍（$162.6M vs $139.2M），Ribbon Communications Inc.净利率更高（54.8% vs 35.5%，领先19.3%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs -10.3%），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -8.1%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
ADMA vs RBBN — 直观对比
营收规模更大
RBBN
是对方的1.2倍
$139.2M
营收增速更快
ADMA
高出28.7%
-10.3%
净利率更高
RBBN
高出19.3%
35.5%
两年增速更快
ADMA
近两年复合增速
-8.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $162.6M |
| 净利润 | $49.4M | $89.1M |
| 毛利率 | 63.8% | 42.9% |
| 营业利润率 | 45.1% | 37.6% |
| 净利率 | 35.5% | 54.8% |
| 营收同比 | 18.4% | -10.3% |
| 净利润同比 | -55.9% | — |
| 每股收益（稀释后） | $0.20 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMARBBN
| Q1 26 | — | $162.6M | ||
| Q4 25 | $139.2M | $227.3M | ||
| Q3 25 | $134.2M | $215.4M | ||
| Q2 25 | $122.0M | $220.6M | ||
| Q1 25 | $114.8M | $181.3M | ||
| Q4 24 | $117.5M | $251.4M | ||
| Q3 24 | $119.8M | $210.2M | ||
| Q2 24 | $107.2M | $192.6M |
净利润ADMARBBN
| Q1 26 | — | $89.1M | ||
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $-12.1M | ||
| Q2 25 | $34.2M | $-11.1M | ||
| Q1 25 | $26.9M | $-26.2M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $-13.4M | ||
| Q2 24 | $32.1M | $-16.8M |
毛利率ADMARBBN
| Q1 26 | — | 42.9% | ||
| Q4 25 | 63.8% | 53.3% | ||
| Q3 25 | 56.3% | 50.1% | ||
| Q2 25 | 55.1% | 49.6% | ||
| Q1 25 | 53.2% | 45.4% | ||
| Q4 24 | 53.9% | 55.7% | ||
| Q3 24 | 49.8% | 52.1% | ||
| Q2 24 | 53.6% | 50.8% |
营业利润率ADMARBBN
| Q1 26 | — | 37.6% | ||
| Q4 25 | 45.1% | 4.1% | ||
| Q3 25 | 38.0% | 1.3% | ||
| Q2 25 | 35.1% | 1.9% | ||
| Q1 25 | 30.4% | -10.8% | ||
| Q4 24 | 32.6% | 13.2% | ||
| Q3 24 | 33.1% | -0.4% | ||
| Q2 24 | 36.6% | -1.0% |
净利率ADMARBBN
| Q1 26 | — | 54.8% | ||
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | -5.6% | ||
| Q2 25 | 28.1% | -5.0% | ||
| Q1 25 | 23.4% | -14.5% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | -6.4% | ||
| Q2 24 | 29.9% | -8.7% |
每股收益（稀释后）ADMARBBN
| Q1 26 | — | $0.50 | ||
| Q4 25 | $0.20 | $0.50 | ||
| Q3 25 | $0.15 | $-0.07 | ||
| Q2 25 | $0.14 | $-0.06 | ||
| Q1 25 | $0.11 | $-0.15 | ||
| Q4 24 | $0.45 | $0.05 | ||
| Q3 24 | $0.15 | $-0.08 | ||
| Q2 24 | $0.13 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $67.6M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $419.1M |
| 总资产 | $624.2M | — |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMARBBN
| Q1 26 | — | $67.6M | ||
| Q4 25 | $87.6M | $96.4M | ||
| Q3 25 | $61.4M | $74.8M | ||
| Q2 25 | $90.3M | $60.5M | ||
| Q1 25 | $71.6M | $71.2M | ||
| Q4 24 | $103.1M | $87.8M | ||
| Q3 24 | $86.7M | $37.2M | ||
| Q2 24 | $88.2M | $64.6M |
总债务ADMARBBN
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | $342.1M | ||
| Q3 25 | $72.4M | $344.3M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $347.4M | ||
| Q4 24 | $72.3M | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M |
股东权益ADMARBBN
| Q1 26 | — | $419.1M | ||
| Q4 25 | $477.3M | $449.0M | ||
| Q3 25 | $431.2M | $360.1M | ||
| Q2 25 | $398.3M | $370.4M | ||
| Q1 25 | $373.4M | $381.8M | ||
| Q4 24 | $349.0M | $404.6M | ||
| Q3 24 | $231.9M | $395.5M | ||
| Q2 24 | $188.3M | $405.0M |
总资产ADMARBBN
| Q1 26 | — | — | ||
| Q4 25 | $624.2M | $1.2B | ||
| Q3 25 | $568.7M | $1.1B | ||
| Q2 25 | $558.4M | $1.1B | ||
| Q1 25 | $510.6M | $1.1B | ||
| Q4 24 | $488.7M | $1.2B | ||
| Q3 24 | $390.6M | $1.1B | ||
| Q2 24 | $376.4M | $1.1B |
负债/权益比ADMARBBN
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | 0.76× | ||
| Q3 25 | 0.17× | 0.96× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | 0.21× | 0.86× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.86× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | — |
| 自由现金流经营现金流 - 资本支出 | $34.6M | — |
| 自由现金流率自由现金流/营收 | 24.8% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | — |
8季度趋势，按日历期对齐
经营现金流ADMARBBN
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $29.2M | ||
| Q3 25 | $13.3M | $26.5M | ||
| Q2 25 | $21.1M | $-795.0K | ||
| Q1 25 | $-19.7M | $-3.5M | ||
| Q4 24 | $50.2M | $61.8M | ||
| Q3 24 | $25.0M | $-14.8M | ||
| Q2 24 | $45.6M | $-9.8M |
自由现金流ADMARBBN
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $27.3M | ||
| Q3 25 | $-1.1M | $21.0M | ||
| Q2 25 | $18.7M | $-6.5M | ||
| Q1 25 | $-24.4M | $-15.7M | ||
| Q4 24 | $47.5M | $53.8M | ||
| Q3 24 | $24.0M | $-23.7M | ||
| Q2 24 | $43.6M | $-12.9M |
自由现金流率ADMARBBN
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 12.0% | ||
| Q3 25 | -0.8% | 9.7% | ||
| Q2 25 | 15.3% | -2.9% | ||
| Q1 25 | -21.2% | -8.7% | ||
| Q4 24 | 40.4% | 21.4% | ||
| Q3 24 | 20.0% | -11.3% | ||
| Q2 24 | 40.7% | -6.7% |
资本支出强度ADMARBBN
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 0.9% | ||
| Q3 25 | 10.7% | 2.6% | ||
| Q2 25 | 2.0% | 2.6% | ||
| Q1 25 | 4.1% | 6.7% | ||
| Q4 24 | 2.3% | 3.2% | ||
| Q3 24 | 0.9% | 4.2% | ||
| Q2 24 | 1.9% | 1.6% |
现金转化率ADMARBBN
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
